Our findings are in accordance with those from other large clinical trials, which showed a strong association of increased lymphocyte infiltration and improved outcomes in more aggressive BC subtypes, such as TN and ER/PgR‐negative/HER2‐positive patients. Here, PGR is linked to breast cancer.